Scotiabank initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics price target lowered to $95 from $120 at Truist
- Roblox downgraded, Pinterest upgraded: Wall Street’s top analyst calls
- Viking Therapeutics price target lowered to $96 from $109 at B. Riley
- Viking Therapeutics: Promising Developments in Clinical Pipeline and Strategic Progress Support Buy Rating
- Viking Therapeutics price target lowered to $70 from $120 at Maxim